Toripalimab Evidence Journey in Cancer Care

By Rene Pretorius

April 9, 2025

The FDA approved toripalimab (Loqtorzi) on October 27, 2023, as the first immunot...
NICE Breakthrough: Record Positive Recommendations for Blood Cancer Treatment...
Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, an...
Engineering Resilience: Mastering Pharma Patent Expiration Strategy
Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefit...
Journavx Market Access Strategy in Focus: What Early Payer Decisions Signal f...
Pharmacy Benefit Managers Report Reveals Escalating Drug Costs and Calls for ...
Reevaluating NICE’s Cost-Effectiveness Thresholds: The QALY Debate
Access to Anti-Obesity Medication for Medicare and Medicaid
Sanofi’s 340B Rebate Model: A Joint Effort to Reform Drug Pricing Pract...
NICE Rejects Donanemab for NHS Use Due to Cost Concerns
Innovative Pricing and Payment Models for Health Technologies
UNAIDS Urges Greater Access for Gilead’s Lenacapavir